疏肝散合汤剂治疗代偿性肝硬化患者的临床效果

摘要

Objective:To study Shugan decoction in compensatory cirrhosis(CC) and its effects on HA,LN and PC Ⅲ.Methods:All 156 patients with CC who were treated from September 2015 to October 2016 in the hospital were enrolled in this study.According to the simple digital random table method,they were randomly divided into an observation group and a control group,each 78cases.The two groups were given comprehensive treatment of liver protection,enzyme reduce and jaundice relieving drugs,and the control group was given lamivudine.The observation group was treated with Shugan powder decoction.After 1 month of treatment,HA,LN,PC Ⅲ,portal vein diameter,spleen thickness,and hepatitis B virus DNA (HBVDNA) quantification as well as adverse reactions in different stages(before and 30 d after treatment)of both groups were compared.Results:The total effective rate of the observation group was 96.15％,significantly higher than that of the control group of 87.18％,and the difference was statistically significant (P ＜ 0.05).After treatment,the levels of HA,LN and PC in the two groups were significantly lower than before treatment,and the observation group after treatment of LN,HA and PC Ⅲ levels were significantly lower than the control group,and the difference was statistically significant (P ＜ 0.05).The diameter of portal vein,spleen thickness and HBVDNA of the two groups after treatment were significantly less than those before treatment,and the diameter of portal vein,spleen thickness and HBVDNA in the observation group were significantly less than those in the control group,with statistically significant difference (P ＜ 0.05).The incidence rate of adverse reactions in the observation group was 2.56％,significantly lower than that of the control group of 10.26％,and the difference was statistically significant (P ＜ 0.05).Conclusion:The curative effect of CC patients were treated with Shugan decoction is obvious and can significantly improve the level of HA,LN and PC Ⅲ,with favorable liver protection function high safety,which is worthy of promotion.%目的:研究疏肝散合汤剂治疗代偿性肝硬化(Compensatory Cirrhosis,CC)患者的临床效果.方法:选择从2015年9月到2016年10月在医院治疗的CC患者156例纳.依据简单数字随机表法将患者观察组和对照组,各78例,2组均给予保肝、降酶和退黄等药物综合治疗,对照组给予拉米夫定,观察组则加用疏肝散合汤剂,2组均治疗1个月后比较疗效和不同时期(治疗前及治疗后30 d)的透明质酸(HA)、层黏蛋白(LN)以及Ⅲ型前胶原(PCⅢ)水平,门脉直径、脾厚度以及乙肝病毒的脱氧核糖核酸(HBVDNA)定量,以及不良反应.结果;观察组的总有效率是96.15％,明显高于对照组的87.18％,差异有统计学意义(P＜0.05).治疗后2组的HA,LN以及PCⅢ水平均分别明显低于治疗前,且观察组治疗后的HA,LN以及PCⅢ水平均明显低于对照组,差异有统计学意义(P＜0.05).治疗后2组的门脉直径、脾厚度以及HBVD-NA定量均明显少于治疗前,且观察组的门脉直径、脾厚度以及HBVDNA定量均明显少于对照组,差异有统计学意义(p＜0.05).观察组不良反应发生率2.56％,明显低于对照组的10.26％,差异有统计学意义(P＜0.05).结论:利用疏肝散合汤对CC患者进行治疗后的疗效较为明显,且能明改善患者的HA,LN以及PCⅢ水平,护肝功能较好,安全性较高.